Ischemic ophthalmopathy is a group of eye disease induced by local and systemic disturbance of blood circulation.The management of ischemic ophthalmopathy is very difficult because of complex etiological factors, multiple target tissue involvement and lack of specific treatment.Compound anisodine injection is domestically developed patented chemicals and has been widely used in the treatment of ischemic ophthalmopathy in past years.However, there are still some limitations in pharmacology study of compound anisodine injection due to the Limited conditions of laboratory research techniques and clinical examination equipments in 1980s.With the rapid development of techniques and equipments in laboratory research and clinical examination during the last decade, some updated concepts and understandings of ischemic ophthalmopathy is constantly being expanded.In recent years, the pharmacokinetics and pharmacodynamics of compound anisodine injection have been further studied and have provided new evidences of tissue distribution following local injection around the eyes.In addition, we have also realized that there are still some insufficiencies existing in clinical practice of compound anisodine injection, including nonstandard use of the drug, and indication lagging behind the clinical research progress, which to some extent affect the evaluation of therapeutic effects of compound anisodine injection.For these reasons, there is a clear necessity for the agreement and guidance on the well-conducted clinical application of compound anisodine injection in ischemic ophthalmopathy based on the Latest development of pharmaceutical research and evidence-based clinical evaluation.